Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

BioNTech reported EUR 6.1 billion in revenue and EUR 3.2 billion in net profit in the third quarter, driven by BioNTech and partner Pfizer's sales of COVID-19 vaccine Comirnaty, and we're maintaining ...

The US Food and Drug Administration has granted emergency use authorization for a booster dose of Pfizer/BioNTech's COVID-19 vaccine for children ages 5 to 11 at least five months after completion of ...

The Food and Drug Administration on Tuesday authorized a second booster of Pfizer-BioNTech and Moderna for adults 50 years and older, announcing that a fourth shot improves protection against severe ...

The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17. It's the first Covid-19 vaccine booster authorized for ...

The number of coronavirus cases, especially of newer omicron variants, are still relatively high in the U.S. The new bivalent version of the Pfizer/BioNTech and Moderna vaccines are now authorized and ...

Numbers from the CDC show nearly 67% of fully vaccinated people over the age of 65 have gotten a booster shot. Pfizer and BioNTech want the FDA to authorize yet another one for that age group. NPR ...

The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17, and the US Centers for Disease Control and Prevention ...

Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...